Joel E Gallant1, Richard D Moore. 1. Department of Medicine, Johns Hopkins University School of Medicine, 1830 E. Monument Street, Baltimore, MD 21205, USA. jgallant@jhmi.edu
Abstract
OBJECTIVES: To determine whether tenofovir disoproxil fumarate (TDF) is associated with renal dysfunction when used as part of an initial antiretroviral regimen and to assess the effect of ritonavir-boosted protease inhibitor (PI/r) coadministration on renal function in TDF-treated patients. DESIGN: Analysis from a prospective observational cohort. METHODS: : We compared all antiretroviral-naive patients with an estimated glomerular filtration rate (eGFR) of more than 50 ml/min per 1.73 m (modification of diet in renal disease equation) who initiated either TDF (n = 201) or any alternative nucleoside reverse transcriptase inhibitor (NRTI) (n = 231) after 1 January 2002. RESULTS: Patients taking both TDF and NRTIs experienced an initial decline in eGFR during the first 180 days of therapy, but eGFR stabilized between 180 and 720 days. There was no difference between TDF and NRTI use in 25 or 50% decline in eGFR at 1 or 2 years or in change in eGFR at 6, 12, or 24 months. Those taking TDF and a PI/r had a greater median decline in eGFR than those taking TDF and a non-NRTI at 6 months (P = 0.01), with trends at 12 (P = 0.08) and 24 months (P = 0.08). There was no difference in median GFR decline between those on an NRTI and PI/r vs. an NRTI and non-NRTI. CONCLUSION: Our data are consistent with results of clinical trials, which have shown no evidence of renal toxicity when TDF is used as part of an initial regimen. Our results support the use of TDF as a component of the initial antiretroviral regimen, and suggest that the eGFR should be monitored more closely when TDF is used with a PI/r.
OBJECTIVES: To determine whether tenofovir disoproxil fumarate (TDF) is associated with renal dysfunction when used as part of an initial antiretroviral regimen and to assess the effect of ritonavir-boosted protease inhibitor (PI/r) coadministration on renal function in TDF-treated patients. DESIGN: Analysis from a prospective observational cohort. METHODS: : We compared all antiretroviral-naive patients with an estimated glomerular filtration rate (eGFR) of more than 50 ml/min per 1.73 m (modification of diet in renal disease equation) who initiated either TDF (n = 201) or any alternative nucleoside reverse transcriptase inhibitor (NRTI) (n = 231) after 1 January 2002. RESULTS:Patients taking both TDF and NRTIs experienced an initial decline in eGFR during the first 180 days of therapy, but eGFR stabilized between 180 and 720 days. There was no difference between TDF and NRTI use in 25 or 50% decline in eGFR at 1 or 2 years or in change in eGFR at 6, 12, or 24 months. Those taking TDF and a PI/r had a greater median decline in eGFR than those taking TDF and a non-NRTI at 6 months (P = 0.01), with trends at 12 (P = 0.08) and 24 months (P = 0.08). There was no difference in median GFR decline between those on an NRTI and PI/r vs. an NRTI and non-NRTI. CONCLUSION: Our data are consistent with results of clinical trials, which have shown no evidence of renal toxicity when TDF is used as part of an initial regimen. Our results support the use of TDF as a component of the initial antiretroviral regimen, and suggest that the eGFR should be monitored more closely when TDF is used with a PI/r.
Authors: Hassane Izzedine; Jean Sebastien Hulot; Daniel Vittecoq; Joel E Gallant; Schlomo Staszewski; Vincent Launay-Vacher; Andrew Cheng; Gilbert Deray Journal: Nephrol Dial Transplant Date: 2005-03-01 Impact factor: 5.992
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Hassane Izzedine; Corinne Isnard-Bagnis; Jean Sébastien Hulot; Daniel Vittecoq; Andrew Cheng; Carmen Kreft Jais; Vincent Launay-Vacher; Gilbert Deray Journal: AIDS Date: 2004-04-30 Impact factor: 4.177
Authors: Joseph Gathe; Barbara A da Silva; Daniel E Cohen; Mona R Loutfy; Daniel Podzamczer; Rafael Rubio; Sara Gibbs; Theresa Marsh; Christian Naylor; Linda Fredrick; Barry Bernstein Journal: J Acquir Immune Defic Syndr Date: 2009-04-15 Impact factor: 3.731
Authors: Babafemi Taiwo; Elizabeth L Yanik; Sonia Napravnik; Patrick Ryscavage; Susan L Koletar; Richard Moore; W Christopher Mathews; Heidi M Crane; Kenneth Mayer; Anne Zinski; James S Kahn; Joseph J Eron Journal: AIDS Date: 2013-06-19 Impact factor: 4.177
Authors: Alana Brennan; Denise Evans; Mhairi Maskew; Saraladevi Naicker; Prudence Ive; Ian Sanne; Thapelo Maotoe; Matthew Fox Journal: AIDS Date: 2011-08-24 Impact factor: 4.177
Authors: Robert C Kalayjian; Bryan Lau; Rhoderick N Mechekano; Heidi M Crane; Benigno Rodriguez; Robert A Salata; Zipporah Krishnasami; James H Willig; Jeffrey N Martin; Richard D Moore; Joseph J Eron; Mari M Kitahata Journal: AIDS Date: 2012-09-24 Impact factor: 4.177
Authors: Michelle M Estrella; Alison G Abraham; Yuezhou Jing; Rulan S Parekh; Phyllis C Tien; Dan Merenstein; Celeste Leigh Pearce; Kathryn Anastos; Mardge H Cohen; Jack A Dehovitz; Stephen J Gange Journal: AIDS Res Hum Retroviruses Date: 2013-01-29 Impact factor: 2.205